To ensure compliance with the EC Grant Agreement and Consortium Agreement, and to ensure that the projects agreed deliverables and milestones are achieved within budget, and on time.
2. To ensure the effective inter-WP alignment of activities and promote efficient and effective internal communication and decision-making.
3. To develop a feasible business plan for the sustainable continuation of the operational infrastructures and processes needed to continue the VALUE-Dx activities well beyond the projects 4-years, and to widen the applicability of study findings beyond the current priority of CA-ARTI in community care settings.
https://value-dx.eu/wp-content/uploads/2019/09/VALUE-Dx_logo_white4.png4281226melanie.hostehttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngmelanie.hoste2020-01-10 14:15:252020-01-10 14:18:20Headway made for Point Prevalence Audit Survey in primary and long-term care settings
https://value-dx.eu/wp-content/uploads/2019/09/VALUE-Dx_logo_white4.png4281226Daniele Pazzolahttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2019-11-21 12:20:002020-01-10 14:18:44IMI article - Technology, not instinct, should guide antibiotic prescribing. A Q&A with Herman Goossens
https://value-dx.eu/wp-content/uploads/2019/10/ERS-web.png238914melanie.hostehttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngmelanie.hoste2019-10-15 14:21:512019-10-15 14:33:51Diagnostics in fighting antimicrobial resistance: A joint session between ESCMID and ERS at the ERS International Congress 2019
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.